Back to Peptide Index

Adipotide-FTPP

Weight LossEvidence Level: researchStrictly for research purposes, not approved by the FDA for clinical use.
Peptide #24

Adipotide-FTPP is a synthetic peptide developed to target and reduce fat deposits selectively. It targets and destroys blood vessels supplying adipose tissue, leading to fat cell starvation and elimination. It is being researched for its potential effectiveness against obesity, metabolic syndrome, and related conditions.

Alternative Names:

Fat-Targeted Proapoptotic Peptide

Overview

Adipotide-FTPP is a synthetic peptide targeting blood vessels of adipose tissue to induce fat cell apoptosis, showing promise in obesity and metabolic syndrome research.

How It Works

Binds to specific proteins on blood vessels of adipose tissues, initiates apoptosis by disrupting blood supply, reduces fat mass.

Clinical Effects

Promotes significant and rapid weight loss, may improve insulin sensitivity and overall metabolic health.

Therapeutic Applications

Obesity management, metabolic syndrome, cancer cachexia.

Research Studies

Clinical Trials

Initial human clinical trials have shown promising results regarding weight reduction and improved metabolic markers.

Preclinical Studies

Animal studies demonstrate marked reduction in fat mass without significant impact on lean body mass.

Frequently Asked Questions

Is Adipotide-FTPP legally available? Yes, for research purposes. Have human trials been conducted? Initial trials show promising results. What side effects? Kidney toxicity, dehydration, fatigue, injection-site reactions. How is it administered? Subcutaneous injections. Can it be combined with other treatments? Needs further study. Does it result in permanent weight loss? Promotes rapid fat loss, long-term management requires lifestyle adjustments.

Quick Information

Safety Information

Safety Profile

Ongoing research aims to further clarify its safety profile and long-term effects.

Contraindications

Side Effects: Mild to moderate kidney toxicity, dehydration, fatigue, mild injection-site reactions. Safety Profile: Ongoing research aims to further clarify its safety profile and long-term effects.

Side Effects

Mild to moderate kidney toxicity, dehydration, fatigue, mild injection-site reactions.

Research References

Kolonin, M.G., et al. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine. Barnhart, K.F., et al. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine. Kim, D.H., et al. (2020). Potential metabolic benefits of targeted adipose tissue reduction. Journal of Metabolic Research.

Additional Resources

View Source